

4-5.10.2018

SHERATON HOTEL,
B. PRUSA 2 STREET, WARSAW

4 OCTOBER 2018 (THURSDAY)

16.00-16.10	Opening – Robert Flisiak
16.10-18.10	Session 1. National hepatologic topics of interest – Jerzy Jaroszewicz, Peter Jarcuska
16.10-16.30	Clinical relevance of haemodynamic response control following drug therapy of portal hypertension – Ivica Grgurević (Croatia)
16.30-16.50	Non-invasive markers of portal hypertension (results of a grant study) – Jan Sperl (Czech Republic)
16.50-17.10	Wilson disease – genetic background and diagnostic challenged in the Polish population – Maciej Dądalski (Poland)
17.10-17.30	Effectivity of primary biliary cirrhosis treatment by UDCA - Slovak experiences – Sylvia Drazilova (Slovakia)
17.30-17.50	Liver transplantation after downstaging of HCC – Tajana Filipec Kanizaj (Croatia)
17.50-18.10	Frailty in liver cirrhosis – Lubomir Skladany (Slovakia)
18.10-18.20	Discussion
18:40	Gathering in the hotel's Lobby and departure for dinner by bus
19.00	Dinner – Warszawski Sznyt Restaurant address: 2 Senatorska Street, Warsaw

5 OCTOBER 2018 (FRIDAY)

13.00-14.30

Lunch

9.00-10.20	Session 2. Searching for hidden virus (microelimination) – Bela Hunyady, Jan Sperl
9.00-9.20	Screening and treatment of HCV in prisoners. Ten years experience in Hungary – Klara Werling (Hungary)
9.20-9.40	Microelimination of HCV in hemodialysed patients and in kidney transplant recipients - Sona Frankova (Czech Republic)
9.40-10.00	Is elimination of HCV feasible in patients with haemophilia and other blood disorders in the short-to-medium term? – Krzysztof Tomasiewicz (Poland)
10.00-10.20	Prisoners screening for HCV - UK experience – Wiliam Rosenberg (United Kingdom)
10.20-10.35	Discussion
10.35-10.50	Coffee break
10.50-12.30	Session 3. Young CEHC – Ivica Grgurević, Krzysztof Tomasiewicz
10.50-11.10	Nonalcoholic fatty liver disease and liver transplantation - where do we stand? – Ivana Mikolasević (Croatia)
11.10-11.30	New basics and advanced diagnosics methods in HCC – Monika Pazgan-Simon (Poland)
11.30-11.50	New imaging techniques to evaluate liver damage in children – Kids4life EU Project – Kamil Janowski (Poland)
11.50-12.10	Usefulness of extracellular matrix proteins serum levels and/or transient elastography in assessment of fibrosis regression after DAAs treatment – Agata Kozłowska (Poland)
12.10-12.30	The influence of DAA therapy on depression and neurocognitive disorders in chronic hepatitis C – Maria Blaszkowska (Poland)
12.30-12.45	Discussion
12.45-13.00	Conclusions and CEHC future plans – Governing Board



STRATEGIC SPONSOR:



SUPPORTING SPONSOR:

MSD MSD





Batumi Conference & Event Agency ul. Sielanki 9A, 02-946 Warszawa tel. + 48 22 885 89 47, e-mail: biuro@batumi-agency.pl

